The Index · Pharma

India AI-Native Index · Edition one · Public evidence only

Sun Pharma

Scored on public evidence published between February 2025 and August 2026, reviewed through 30 August 2026, under the Edition 1 locked rule set (ANS-100/P v2.1, 1-floor on every question). Provisional result and evidence annexure sent to the company fourteen days before publication.

AI AssistedBand · 21–40
CConfidence · 3 of 8 evidence categories
Band onlyPublication form

Published as a band; the shaded band is the entry.

Because public-evidence coverage was Grade C, no precise score or ordinal position is published. Public-evidence band: Limited Visibility — the band shown records what the public record contained during the evidence window.

What this assessment is, and is not

The Index measures what a company has placed on the public record about its use of AI, within the evidence window, against a published rubric. It does not measure business performance, product quality, safety, customer outcomes, or the adequacy of internal controls. A low score on any question means that, in the public sources listed below, reviewed through the cut-off date, disclosure sufficient to satisfy the published criterion was not located. The company may maintain relevant practices or controls that are not publicly disclosed.

Evidence located

Questions on which the reviewed public sources contained disclosure meeting at least the level-2 anchor of the published rubric:

Level 2 — disclosed; not quantified or independently verified

  • internal AI tooling in use
  • AI deployed across functions
  • AI leadership and organisation

Level descriptions are those of the published rubric. The evidence annexure sent to the company lists the specific documents and passages relied on for each question.

Where disclosure meeting the criterion was not located

In the public sources listed below, reviewed through 30 August 2026, we did not locate disclosure sufficient to satisfy the Index's published criterion for the following. The company may maintain relevant practices or controls that are not publicly disclosed.

  • named AI platform or knowledge substrate
  • production AI autonomy
  • orchestration or integration platform
  • guardrail and evaluation documentation
  • model strategy or vendor architecture
  • hosting or infrastructure posture
  • open or external build surface
  • evaluation and benchmarking practice
  • API or integration surface
  • canonical data platform
  • AI governance posture
  • AI talent or training figures
  • role redesign around AI
  • AI-specific investment (a single statement of intent or unquantified claim was located and is cited in the annexure)
  • AI attribution to reported economics
  • improvement trail and versioning
  • AI-native monetisation
  • position on agentic or AI-mediated exposure
  • product that could not exist before AI, with volumes
  • leadership commitment and strategic response

Sources reviewed

FY2025-26 Annual Report — main PDF, Chairman & MD's Message and MD&A, Board's Report and Corporate Governance (sunpharma.com, Jul 2026); Q3 and Q4/FY26 results releases (company PDFs); FY26 full-year coverage; ChartAlert analyst assessment; AGM notice

Exchange filings and reports relied on:

All sources archived at scoring date; the complete source archive register is available on request via corrections@thecompounding.company. Short quotations, where used, are attributed and used for the purpose of review. Right-of-reply notice sent 10 September 2026 to the Company Secretary, Investor Relations, registered office, corporate communications and legal function. Company response: none received as at publication. No response is characterised as agreement or endorsement.

This assessment is based exclusively on public information available during the stated evidence window. It does not assess undisclosed internal systems or practices. Scores and bands are opinions produced by applying the published rubric to the cited factual record. Not investment advice. The Index is not affiliated with, endorsed by, or sponsored by any assessed company.

Corrections: material factual errors are corrected promptly and logged. See the corrections log and the methodology, including its removal policy.